COVID-19 Tech Collaborations: Adaptive And Microsoft Map Immune System Responses

A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.

technology collaboration

Sequencing immune cell responses to diseases and mapping those responses to the specific antigens that triggered them, could help prevent the spread of future infectious diseases. “The human immune system is the best detection mechanism there is,” said Harlan Robins, chief scientific officer and co-founder of Adaptive Biotechnologies Corporation. Adaptive’s ongoing partnership with Microsoft, which is producing results on differing immune responses to COVID-19, is an example of how technology sector tools, specifically machine learning, can be leveraged in the fight against disease. “We have warning systems for viral computer threats, we just don't have any for actual viral threats,” said Robins.

The successful sequencing of the human genome at the turn of the millennium ushered in a new era of genomic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.